Labor's decision to proceed with capital gains tax (CGT) changes without finalizing details on carve-outs for startups has raised concerns among top-tier medical scientists, who are reconsidering bringing their talents to Australia. The uncertainty surrounding the CGT changes has alarmed the biotech sector, as reported by the Australian Financial Review on May 28, 2026.
According to the article, the lack of clarity on exemptions for startup investments could deter high-caliber researchers and entrepreneurs from relocating to Australia, potentially impacting the country's biotech innovation. The government has not yet provided specific details on which startups or investments would qualify for carve-outs, leaving the sector in limbo.
Industry leaders have warned that without clear protections, Australia risks losing competitive edge in biotechnology, a field where attracting global talent is crucial. The Australian Biotech Association has called for urgent consultations with the government to address these concerns.
